Phase I Safety Study of DMXAA in Refractory Tumors
NCT00856336
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Refractory Tumors
Interventions
DRUG:
DMXAA
Sponsor
Antisoma Research